IXICO partner with Microsoft to enhance AI platform
pharmafile | October 20, 2021 | News story | Research and Development |
IXICO, an AI data analytics company delivering insights into neuroscience, have announced a collaboration with Microsoft to develop its AI data analytics platform for the global pharmaceutical industry.
A leading neuroimaging provider, IXICO helps biopharmaceutical companies maximise the value of their drug development pipelines by transforming data into clinically meaningful insights. Their analytics and insights enable the acceleration of R&D decision making, de-risk clinical research, and maximise the value of sponsor’s drug development pipelines.
IXICO’s portfolio of AI data analytics and scientific expertise in neurological diseases, combined with Microsoft’s cloud-based AI infrastructure, will provide a significant enabler for IXICO’s delivery of clinical trial analytics solutions to the pharmaceutical industry.
As part of the collaboration, the two companies will work together to deliver IXICO’s AI solutions into global clinical trials for neurological diseases such as Alzheimer’s and Huntington’s disease, by enhancing IXICO’s large-scale data processing capabilities. These capabilities will set the foundation for an expanded range of differentiated and proprietary AI driven services, assisting IXICO’s customers in their efforts to address significant unmet medical needs.
Laura Robinson, Health and Life Sciences Director at Microsoft UK, has commented: “Microsoft is working with companies in the life science sector to develop capabilities and maximise the positive impact of data and AI. IXICO and Microsoft are both focused on using technology to deliver better outcomes in this critical area.”
Guilio Cerroni, CEO at IXICO, stated: “The partnership with Microsoft ensures we remain at the forefront of data analytics required by our global pharmaceutical clients, to provide new and valuable insights to reduce both the high cost of drug development, and the time to market for urgently needed drugs across a wide range of neurological diseases.”
Ana Ovey
